SITC is excited to kick off our annual spring Capitol Hill visits! Similar to years past, SITC volunteers will be meeting with their home offices to discuss and advocate for inclusion of specific report language into the FY25 appropriation bills that fund the federal government. Traditionally, SITC has advocated for language directed at the National Cancer Institute (NCI) and Food & Drug Administration (FDA) urging them to prioritize pressing topics related to the field of Immunotherapy. This year's language is focused on the timing and sequencing of Immunotherapy. As new data arrives surrounding the efficacy of treating patients with Immunotherapy in earlier stages of disease, SITC is ensuring that the field focuses on this critical area of IO research. In order to support this, SITC is advocating for language that asks NCI to prioritize early-stage and neo-adjuvant Immunotherapy research over the coming year. SITC is also advocating for language directed at the FDA encouraging guidance to the field on how to validate biomarkers for early disease detection and characterization, as well as guidance for implementation of early disease clinical trial endpoints.
This year's appropriations language can be found in its entirety here: SITC FY25 Appropriations Language.pdf
SITC is excited to share updates and further news related to our hill visits over the next coming weeks.